

# Matthew Wright

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5644243/matthew-wright-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68

papers

1,514

citations

22

h-index

36

g-index

77

ext. papers

1,656

ext. citations

3.9

avg, IF

3.98

L-index

#	Paper	IF	Citations
68	Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2S(methylsulfonyl)-[1,1Sbiphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. <i>Journal of Medicinal Chemistry</i> , <b>2001</b> , 44, 566-70	8.3	155
67	Rational use of plasma protein and tissue binding data in drug design. <i>Journal of Medicinal Chemistry</i> , <b>2014</b> , 57, 8238-48	8.3	105
66	Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 4405-18	8.3	76
65	Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. <i>Journal of Medicinal Chemistry</i> , <b>1999</b> , 42, 2760-73	8.3	76
64	Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2S(aminosulfonyl)[1,1Sbiphenyl]-4-yl]-1H-pyrazole-5-carboxamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1). <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 5298-315	8.3	65
63	Isoxazolines and isoxazoles as factor Xa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2000</b> , 10, 685-9	2.9	62
62	Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 303, 993-1000	4.7	52
61	Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 1194-203	5.9	49
60	Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. <i>Current Drug Metabolism</i> , <b>2006</b> , 7, 119-26	3.5	46
59	Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2000</b> , 43, 4398-415	8.3	44
58	Nonsymmetric P2/P2Scyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues. <i>Journal of Medicinal Chemistry</i> , <b>1998</b> , 41, 2411-23	8.3	44
57	Optimizing the use of cyclosporine in renal transplantation. <i>Clinical Biochemistry</i> , <b>1995</b> , 28, 195-211	3.5	43
56	Improved high-performance liquid chromatographic assay method for the enantiomers of ibuprofen. <i>Biomedical Applications</i> , <b>1992</b> , 583, 259-65		39
55	Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities. <i>Drug Metabolism and Disposition</i> , <b>2019</b> , 47, 1122-1135	4	36
54	Limited extent of stereochemical conversion of chiral non-steroidal anti-inflammatory drugs induced by derivatization methods employing ethyl chloroformate. <i>Biomedical Applications</i> , <b>1993</b> , 616, 59-65		34
53	Effect of the enantiomers of flurbiprofen, ibuprofen, and ketoprofen on intestinal permeability. <i>Journal of Pharmaceutical Sciences</i> , <b>1996</b> , 85, 1170-3	3.9	33
52	Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. <i>Chemistry and Biology</i> , <b>1998</b> , 5, 597-608		32

51	Synthesis, antiviral activity and pharmacokinetics of P1/P1Substituted 3-aminoindazole cyclic urea HIV protease inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2003</b> , 13, 605-8	2.9	26
50	The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. <i>Drug Metabolism and Disposition</i> , <b>2004</b> , 32, 1359-69	4	25
49	Nonbenzamidine tetrazole derivatives as factor Xa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2003</b> , 13, 369-73	2.9	25
48	Differences in NSAID tolerability profiles. Fact or fiction?. <i>Drug Safety</i> , <b>1994</b> , 10, 183-95	5.1	25
47	Proof of concept for the reduction of classical swine fever infection in pigs by a novel viral polymerase inhibitor. <i>Journal of General Virology</i> , <b>2009</b> , 90, 1335-1342	4.9	22
46	Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2008</b> , 18, 1388-91	2.9	20
45	Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans. <i>Biopharmaceutics and Drug Disposition</i> , <b>2016</b> , 37, 93-106	1.7	20
44	Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 1067-73	4	19
43	Methods for the analysis of enantiomers of racemic drugs application to pharmacological and pharmacokinetic studies. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>1993</b> , 29, 1-9	1.7	19
42	Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group. <i>Neuro-Oncology</i> , <b>2005</b> , 7, 183-8	1	18
41	Comparing Mechanistic and Preclinical Predictions of Volume of Distribution on a Large Set of Drugs. <i>Pharmaceutical Research</i> , <b>2018</b> , 35, 87	4.5	17
40	Tricyclic HIV integrase inhibitors: VI. SAR studies of Benzyl flippedSC3-substituted pyrroloquinolines. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2009</b> , 19, 1187-90	2.9	17
39	Rationale for the development of stereochemically pure enantiomers: are the R enantiomers of chiral nonsteroidal anti-inflammatory drugs inactive?. <i>Journal of Pharmaceutical Sciences</i> , <b>1994</b> , 83, 911-23.9	3.9	15
38	Toxicokinetics of indomethacin-induced intestinal permeability in the rat. <i>Pharmacological Research</i> , <b>1997</b> , 35, 499-504	10.2	14
37	SAR studies on a novel series of human cytomegalovirus primase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2007</b> , 17, 2188-92	2.9	14
36	Improving Confidence in the Determination of Free Fraction for Highly Bound Drugs Using Bidirectional Equilibrium Dialysis. <i>Journal of Pharmaceutical Sciences</i> , <b>2019</b> , 108, 1296-1302	3.9	14
35	In vitro and in vivo characterization of CYP inhibition by 1-aminobenzotriazole in rats. <i>Biopharmaceutics and Drug Disposition</i> , <b>2016</b> , 37, 200-11	1.7	13
34	The de novo design and synthesis of cyclic urea inhibitors of factor Xa: optimization of the S4 ligand. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2000</b> , 10, 301-4	2.9	13

33	Prediction of the Pharmacokinetics of Pravastatin as an OATP Substrate Using Plateable Human Hepatocytes With Human Plasma Data and PBPK Modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2018</b> , 7, 251-258	4.5	12
32	A novel series of IKK $\beta$ inhibitors part I: Initial SAR studies of a HTS hit. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2011</b> , 21, 417-22	2.9	11
31	Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2003</b> , 13, 1023-8	2.9	11
30	Entering the era of computationally driven drug development. <i>Drug Metabolism Reviews</i> , <b>2020</b> , 52, 283-298	7.8	10
29	Linearity of metoclopramide kinetics at doses of 5-20 mg. <i>British Journal of Clinical Pharmacology</i> , <b>1988</b> , 26, 469-73	3.8	10
28	Strategies to optimize drug half-life in lead candidate identification. <i>Expert Opinion on Drug Discovery</i> , <b>2019</b> , 14, 221-230	6.2	9
27	Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associated kinase-4. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2015</b> , 25, 5546-50	2.9	9
26	An IQ Consortium Perspective on The Scientific Committee on Health, Environmental and Emerging Risks Final Opinion on the Need for Nonhuman Primates in Biomedical Research, Production and Testing of Products and Devices (Update 2017). <i>Toxicologic Pathology</i> , <b>2019</b> , 47, 649-655	2.1	8
25	Tricyclic HIV integrase inhibitors V. SAR studies on the benzyl moiety. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2009</b> , 19, 2263-5	2.9	8
24	Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance. <i>Clinical Pharmacology and Therapeutics</i> , <b>2008</b> , 84, 660; author reply 661	6.1	8
23	Changes in Organic Anion Transporting Polypeptide Uptake in HEK293 Overexpressing Cells in the Presence and Absence of Human Plasma. <i>Drug Metabolism and Disposition</i> , <b>2020</b> , 48, 18-24	4	8
22	Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2020</b> , 9, 332-341	4.5	7
21	Discovery of a novel series of inhibitors of human cytomegalovirus primase. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2006</b> , 16, 4879-83	2.9	7
20	Dose-dependency of flurbiprofen enantiomer pharmacokinetics in the rat. <i>Journal of Pharmaceutical Sciences</i> , <b>1994</b> , 83, 1077-80	3.9	7
19	Effect of haemodialysis on metoclopramide kinetics in patients with severe renal failure. <i>British Journal of Clinical Pharmacology</i> , <b>1988</b> , 26, 474-7	3.8	7
18	Mixed Matrix Method Provides A Reliable Metabolite Exposure Comparison for Assessment of Metabolites in Safety Testing (MIST). <i>Drug Metabolism Letters</i> , <b>2017</b> , 11, 21-28	2.1	7
17	A novel series of IKK $\beta$ inhibitors part II: description of a potent and pharmacologically active series of analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2011</b> , 21, 423-6	2.9	6
16	A chronic bile duct and intravenous cannulation model in conscious rabbits for pharmacokinetic studies. <i>Journal of Investigative Surgery</i> , <b>2002</b> , 15, 81-9	1.2	6

15	Glucuronidation in the chimpanzee ( <i>Pan troglodytes</i> ): studies with acetaminophen, oestradiol and morphine. <i>Xenobiotica</i> , <b>2006</b> , 36, 1178-90	2	5
14	Characterization of sandwich-cultured hepatocytes as an in vitro model to assess the hepatobiliary disposition of copper. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 969-76	4	4
13	Determination of ritodrine in biological fluids of the pregnant sheep by fused-silica capillary gas chromatography using electron-capture detection. <i>Biomedical Applications</i> , <b>1991</b> , 565, 225-36		4
12	Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 7045-7059	8.3	4
11	Exposure-Effect Relationships in Established Rat Adjuvant-Induced and Collagen-Induced Arthritis: A Translational Pharmacokinetic-Pharmacodynamic Analysis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2019</b> , 369, 406-418	4.7	3
10	Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound. <i>Pharmaceutical Research</i> , <b>2017</b> , 34, 2403-2414	4.5	3
9	Increased cyclosporine bioavailability from a microemulsion formulation in a liver transplant recipient. <i>Annals of Pharmacotherapy</i> , <b>1994</b> , 28, 962-3	2.9	3
8	Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. <i>Chemistry and Biology</i> , <b>1998</b> , 5, R312		2
7	Bioequivalence: Stereochemical Considerations. <i>Clinical Research and Regulatory Affairs</i> , <b>1993</b> , 10, 1-11		2
6	Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat. <i>Drug Metabolism Letters</i> , <b>2016</b> , 10, 91-100	2.1	2
5	Evaluation of the predictive performance of physiologically based pharmacokinetic models for intramuscular injections of therapeutic proteins. <i>Xenobiotica</i> , <b>2019</b> , 49, 1423-1433	2	1
4	Implications of chirality on pharmacodynamic modeling. <i>Chirality</i> , <b>1994</b> , 6, 467-471	2.1	1
3	Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947. <i>Drug Metabolism and Disposition</i> , <b>2020</b> , 48, 408-419	4	1
2	Conformationally Constrained Tricyclic HIV Integrase Inhibitors 239-254		1
1	Molecular recognition of cyclic HIV protease inhibitors: highly orally-bioavailable DMP851 <b>1999</b> , 831-832		